Keitma / Shutterstock.com
5 June 2019Big Pharma
German court deals blow to Sanofi over cholesterol drug
A German court has rejected a bid from French pharmaceutical company Sanofi to have a patent infringement case dismissed.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
12 July 2019 A German court has found that Sanofi’s high-cholesterol treatment, Praluent, infringes one of Amgen’s patents.
Americas
15 August 2019 Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.
Americas
29 August 2019 A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.
Editor's picks
Editor's picks
Big Pharma
12 July 2019 A German court has found that Sanofi’s high-cholesterol treatment, Praluent, infringes one of Amgen’s patents.
Americas
15 August 2019 Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.
Americas
29 August 2019 A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.
Big Pharma
12 July 2019 A German court has found that Sanofi’s high-cholesterol treatment, Praluent, infringes one of Amgen’s patents.
Americas
15 August 2019 Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.
Americas
29 August 2019 A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.